Expressive

rs11960484 - C5orf67 - MAP3K1

Magnitude 2.2 · 1 study on file

Reported associations

  • Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome‐Wide Association Meta‐Analysis Followed by Mendelian Randomization - Unknown journal (n.d.) · Unknown authors · PubMed 37096546

    ABSTRACT: Objective In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors. Methods A genome‐wide association study meta‐analysis was performed of circulating sclerostin levels in 33,961 European individuals. Mendelian randomization (MR) was used to predict the causal effects of sclerostin lowering on 15 atherosclerosis‐related diseases and risk factors. Results We found that 18 conditionally independent variants were associated with circulating sclerostin. Of these, 1 cis signal in SOST and 3 trans signals in B4GALNT3, RIN3, and SERPINA1 regions showed directionally opposite signals for sclerostin levels and estimated bone mineral density. Variants with these 4 regions w

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Screening

  • Coronary artery calcification screening Low

    Genetic association with lower sclerostin predicts increased coronary artery calcification and myocardial infarction risk via Mendelian randomization

    Discuss coronary artery calcium scoring with your physician if indicated by age or risk factors

  • Blood pressure monitoring Moderate

    Genetic association with lower sclerostin predicts increased hypertension risk via Mendelian randomization

    Regular blood pressure checks at least annually

  • Type 2 diabetes screening Moderate

    Genetic association with lower sclerostin predicts increased type 2 diabetes risk via Mendelian randomization

    Fasting glucose and hemoglobin A1c annually